AI Article Synopsis
- The study involved 80 patients with cirrhosis and advanced hepatocellular carcinoma, comparing the effects of tamoxifen against a placebo.
- Both groups were evaluated for similar demographic and clinical factors, ensuring a fair comparison of results.
- The trial concluded that tamoxifen does not significantly improve the 1-year survival rate of these patients, with rates being 30% for tamoxifen and 37.8% for placebo, and noted that tamoxifen was well tolerated.
Article Abstract
To discover whether tamoxifen is able to extend the survival of patients with advanced hepatocellular carcinoma, we included 80 patients with cirrhosis and advanced hepatocellular carcinoma in a multicenter, double-blind, placebo-controlled trial in order to analyze the influence of treatment with tamoxifen on survival. The patients were randomized to receive tamoxifen, 40 mg/day (group 1), or placebo (group 2). Both groups were similar in age, sex, etiology of cirrhosis, biochemical, hematologic and hormonal parameters, morphology of the tumor (nodular vs multinodular or massive), Child-Pugh's score, and Okuda's stage. The 1-year survival rate was similar in both groups (30% in group 1 vs 37.8% in group 2; p = 0.31). Tamoxifen treatment was well tolerated by the patients. We conclude that tamoxifen does not extend the survival of patients with cirrhosis and advanced hepatocellular carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00004836-199804000-00010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!